ESTRO 2024 - Abstract Book

S614

Clinical - Breast

ESTRO 2024

MT does not seem to influence the FCR in patients with breast cancer undergoing adjuvant RT. Its complexity and multidimensionality may need more precise psychological interventions to be tested in the future. The use of the FCRI is encouraged in future studies in order to better assess this parameter.

Keywords: musictherapy, cancer recurrence fear, radiotherapy

2105

Digital Poster

Pregnancy in BRCA-carrier patients after breast cancer therapy: single-centre real-world experience

Beatrice Bettazzi 1 , Luca Visani 1 , Francesca Gensini 2 , Emanuela Olmetto 1 , Pietro Garlatti 1 , Isacco Desideri 1 , Erika Scoccimarro 1 , Vanessa Di Cataldo 1 , Pierluigi Bonomo 1 , Anna Peruzzi 1 , Giulio Frosini 1 , Luisa Caprara 1 , Marianna Valzano 1 , Marco Bernini 2 , Lorenzo Orzalesi 2 , Jacopo Nori 2 , Simonetta Bianchi 2 , Carlotta Becherini 1 , Viola Salvestrini 1 , Lorenzo Livi 1 , Icro Meattini 1 1 Radiation Oncology, Azienda Ospedaliero Universitaria Careggi, Università di Firenze, Firenze, Italy. 2 Breast Unit, Florence University Hospital, Firenze, Italy

Purpose/Objective:

The impact of chemotherapy on reducing fertility still has a strong emotional impact on women with breast cancer, especially if they express the desire to have children. It is therefore increasingly imperative to preserve fertility, especially now that breast cancer is frequently diagnosed in women under the age of 40. This category most frequently includes patients carrying a BRCA gene mutation, who require massive surgery that affects fertility (prophylactic oophorectomy). In our study we analysed data on fertility and pregnancy in BRCA mutated patients previously treated for breast cancer.

Material/Methods:

We retrospectively collected data on a cohort of consecutive BRCA-mutated patients treated for breast cancer in our centre from 2001 to 2020. We asked these women whether or not they had become pregnant after breast cancer treatments, data on type and timing of birth, miscarriages, foetal and/or birth and/or delivery complications, use of endocrine therapy for ovarian preservation and/or adjuvant purposes, use of assisted reproductive technology (i.e., in vitro fertilization and embryo transfer, egg donation).

Results:

The cohort we analysed consisted of 32 patients, with a primary diagnosis at ≤40 years (median age 34 years, range 27-40 years); all of them underwent breast surgery and 28 patients received neoadjuvant or adjuvant chemotherapy. Baseline characteristics are summarised in table 1 . Seven of the 32 patients had at least one